Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death

Navaratnam, S.; Kliewer, Erich V.; Butler, James R.G.; Demers, Alain; Musto, Grace; Badiani, Ketan

doi:10.1016/j.lungcan.2010.01.012

Cited by 24 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That finding may be a result of the small sample size; however, we determined that median survival times for stages iii and iv elderly nsclc patients were both improved with chemotherapy. The median survival time for all advanced nsclc patients on platinum-based chemotherapy has been reported to be 36 weeks 17,18 , which is comparable to the median survival time of 45.8 weeks observed for the elderly nsclc cohort in the present study. That observation indicates that, where appropriate, chemotherapy should be considered for all advanced nsclc patients regardless of age.…”

Section: Discussionsupporting

confidence: 84%

Survival and Treatment Patterns in Elderly Patients with Advanced Non-Small-Cell Lung Cancer in Manitoba

et al. 2011

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death worldwide. Non-small-cell lung cancer (nsclc) is the most common form of lung cancer, with a median age at diagnosis of 70 years. These elderly patients are often underrepresented in the randomized clinical trials upon which chemotherapy plans are based. The objective of the present study was to determine the patterns of treatment and survival in elderly patients with advanced nsclc in Manitoba. An eligible cohort of elderly patients over 70 years of age at diagnosis (n = 497) with advanced nsclc was identified from the provincial cancer registry database for the period 2001–2004. Of the 497 patients identified, only 147 had been evaluated by a medical oncologist, and 82 of the 147 had received chemotherapy treatment, which is 16.5% of the initial cohort. Patients who received chemotherapy were younger than those who did not receive chemotherapy. Most patients receiving chemotherapy (84%) received doublet chemotherapy, with an almost equal split between cisplatin and carboplatin treatment. The median survival times for patients in this cohort were 64 weeks (stage iii nsclc) and 56 weeks (stage iv) with chemotherapy treatment, and 46 weeks (stage iii) and 26 weeks (stage iv) without chemotherapy. Although 50% of patients with advanced nsclc are more than 70 years of age, few are evaluated by a medical oncologist and even fewer are treated with chemotherapy. However, it should be noted that, in the elderly patients who were treated, survival times are comparable to those experienced by younger patients, which is indicative of a benefit of chemotherapy treatment for those elderly patients.

show abstract

Section: Discussionsupporting

confidence: 84%

Survival and Treatment Patterns in Elderly Patients with Advanced Non-Small-Cell Lung Cancer in Manitoba

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Follow-up costs were calculated by multiplying the monthly cost of the disease state "progression free" (Table 5) by the TTP of each anticancer treatment [19,[21][22][23][24][25][26][28][29][30][31][32][33][34][35][36]. Therefore, higher follow-up costs were found for anticancer treatments that ensured a longer period without progression such as cisplatin+docetaxel (€1246) or bevaciz umab+carboplatin+paclitaxel (€1152) ( Table 6).…”

Section: Use Of Resources and Costs Of Treatmentmentioning

confidence: 99%

“…In contrast, lower follow-up costs were associated with erlotinib (€420-€436) and docetaxel (€358-€529) because the TTP was shorter. In the case of follow-up costs associated with BSC, these were calculated by multiplying the monthly cost of the disease state "end-of-life BSC" (Table 5) by the median time from the end of active treatment until death (3.5 months) [36], resulting in a total cost of €556 (Table 6).…”

Section: Use Of Resources and Costs Of Treatmentmentioning

confidence: 99%

Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In contrast, Isla et al [20] in 2011 applied a Delphi panel and obtained € 3,410 as lifetime cost (median 3.5 months) of BSC in advanced NSCLC in Spain. Navaratam et al [21] performed a database analysis including chart reviews and obtained a figure of $CAN 8,654 as total expenses for 1 period of BSC (median 13.8 weeks). There are also 2 studies using a Markov model, published in 2008 and 2010, on the lifetime total cost in hepatocellular cancer, yielding costs of $CAN 10,376 ± 1,649 and $US 7,804 ± 1,349, respectively [22,23].…”

Section: Discussionmentioning

confidence: 99%

Best Supportive Care from the Conservative/Non-Surgical Perspective and Its Costs in the Treatment of Patients with Advanced Medullary Thyroid Cancer: Results of a Delphi Panel

Kreißl

Jacob²,

Führer

et al. 2014

Oncol Res Treat

View full text Add to dashboard Cite

Background: Medullary thyroid cancer (MTC) is a rare tumor entity. The contents of best supportive care (BSC) have not been defined in advanced MTC. The objective of this work is to describe the epidemiology, the treatment patterns with respect to symptom management, as well as palliative treatment and associated costs. Method: A Delphi panel with 9 clinical experts experienced in treating MTC was conducted to obtain details on the epidemiology of MTC and to gain insights into the therapeutic options considered for BSC in advanced MTC in Germany. Unit costs were applied to the described resources from the perspective of the German National Healthcare System in 2011. Results: The annual incidence of MTC in Germany was estimated at about 220. 32% of all patients were estimated to have aggressive/symptomatic MTC, with an estimated mean survival of 36.7 months (median: 36 months). The core element of BSC is relief of symptoms to maintain quality of life. The total mean cost of BSC per patient/year was estimated at € 9,248, lifetime cost at € 28,283. Conclusion: There was consistent agreement within the panel on the epidemiology of MTC and on the structure of the provided therapeutic measures for BSC in advanced MTC, also defining the management of symptoms as a crucial goal of treatment.

show abstract

Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death

Abstract: The largest overall component of cost after the end of chemotherapy was hospitalizations. Effective new therapies that reduce the episodes of hospitalizations would have a significant impact on decreasing aggregate costs.

Cited by 24 publications

References 23 publications

Survival and Treatment Patterns in Elderly Patients with Advanced Non-Small-Cell Lung Cancer in Manitoba

Survival and Treatment Patterns in Elderly Patients with Advanced Non-Small-Cell Lung Cancer in Manitoba

Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel

Best Supportive Care from the Conservative/Non-Surgical Perspective and Its Costs in the Treatment of Patients with Advanced Medullary Thyroid Cancer: Results of a Delphi Panel

Contact Info

Product

Resources

About